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Abstract The Protein Structural Initiative (PSI) at the US
National Institutes of Health (NIH) is funding four large-
scale centers for structural genomics (SG). These centers
systematically target many large families without structural
coverage, as well as very large families with inadequate
structural coverage. Here, we report a few simple metrics
that demonstrate how successfully these efforts optimize
structural coverage: while the PSI-2 (2005-now) contrib-
uted more than 8% of all structures deposited into the PDB,
it contributed over 20% of all novel structures (i.e.
structures for protein sequences with no structural repre-
sentative in the PDB on the date of deposition). The
structural coverage of the protein universe represented by
today’s UniProt (v12.8) has increased linearly from 1992 to
2008; structural genomics has contributed significantly to
the maintenance of this growth rate. Success in increasing
novel leverage (defined in Liu et al. in Nat Biotechnol
25:849–851, 2007) has resulted from systematic targeting
of large families. PSI’s per structure contribution to novel
leverage was over 4-fold higher than that for non-PSI
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structural biology efforts during the past 8 years. If the
success of the PSI continues, it may just take another
*15 years to cover most sequences in the current UniProt
database.
Keywords Protein structure determination 
Structural genomics  Evolution  Protein universe
Abbreviations
3D Three-dimensional
3D structure Here used exclusively to refer to the three-
dimensional coordinates of each atom in the
native conformation of a protein
HTP High-throughput
JCSG Joint Center for Structural Genomics
MCSG Midwest Center for Structural Genomics
NESG Northeast Structure Genomics Consortium
PDB Protein Data Bank of experimentally
determined 3D structures of proteins
PSI Protein structure initiative at the
NIH-NIGMS
NYSGXRC New York Structural GenomiX Research
Consortium
SG Structural genomics
UniProt Unification of SWISS-PROT, TrEMBL and
PIR protein sequence database
Introduction
Systematic targeting of the largest families
without structural coverage
The US contribution to Structural Genomics (SG), the
Protein Structure Initiative (PSI), is funded by the National
Institutes of Health-National Institute of General Medical
Sciences (NIH-NIGMS). The second 5-year phase of the
initiative, PSI-2, began in 2005. Four large-scale Structural
Genomics Centers were created for high-throughput pro-
duction of protein structures (JCSG, MCSG, NESG,
NYSGXRC), as well as six Specialized Research Centers
both charged with continuing to develop technologies
needed for large-scale protein structure determination [30].
The four large-scale production centers are currently
poised to generate over 3,000 entirely new experimental
3D structures of proteins for the biomedical research
community in addition to the over 1,300 structures that
originated from the pilot phase. At the end of the first 3 of
those 5 years, the four centers had already deposited almost
2,000 new 3D structures (data from TargetDB, [9]).
Through the development and advancements of bio-
chemical, robotic, NMR, crystallographic and computational
techniques, SG centers are decreasing the cost and time
required to determine a protein structure in order to advance
the structural coverage of sequence space and biomedical
research. The development and advancement of high-
throughput protein production and protein structure deter-
mination pipelines are critical to the eventual characterization
of protein structure space, expanding our understanding of
molecular evolution, and to address biomedical problems
such as drug discovery.
The challenges from these objectives for computational
biology are mainly twofold: (1) identify targets for which
each experimental structure will have a high leverage for
modeling and (2) focus on those targets that will likely
yield structures using current HTP methods [14, 21,
23, 37].
Metrics of success
Several metrics of success have been developed to monitor
the evolution of structural genomics during PSI [8, 18, 22].
These include (i) total numbers of PDB depositions, (ii)
numbers of distinct sequences (\98% pairwise sequence
identity) for which an experimental structure is determined,
(iii) numbers of ‘novel structures’, defined as a structure for
a protein having\30% sequence identity with any protein
structure already in the PDB, (iv) first 3D structure from a
particular domain family; (v) first 3D structure from a
particular functional class of proteins, (vi) protein struc-
tures which provide a novel testable hypothesis about
function, and other metrics. In the following paragraphs we
outline some of these metrics relating to the value of
experimental 3D structures to provide useful structural
information about homologous protein sequences.
Modeling leverage of experimental structures
Homologous proteins from different organisms, defined as
those that have evolved from a common recent ancestral
protein, usually share similar 3D structures [10, 28, 31, 35].
Therefore, the PSI does not aim at producing structures of
every protein from every organism. Instead, the PSI aims to
identify structural domains in proteins, systematically
organize these protein domains into sequence-structure
families, and determine the 3D structure of one or a few
representatives from many of these families. The ultimate
goal is to attain structural coverage for every major protein
domain family found in nature.
Almost 50,000 experimentally determined 3D structures
have been deposited into the PDB [4]. However, this
accounts for less than 1% of the *6 million protein
sequences deposited into UniProt [2]. As genome
sequencing technologies advance, sequence data is being
generated at an ever increasing pace, not only for complete
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genomes of organisms but even for entire ecologies of
hundreds or thousands of microorganisms (META
genomics) [12, 36, 39]. Accordingly, the rate of discovery
of new protein sequences will continue to increase much
faster that the rate of protein structure determination.
The fact that homologous protein domains have similar
structures enables the application of homology, or com-
parative, modeling methods [17, 32]. Comparative
modeling leverages in the information provided by each
experimental structure many fold. For example, it has been
proposed that experimental determination of 3D structures
for one representative of the largest 1,000–2,000 protein
domain families, would be sufficient to allow modeling, at
some approximate level, of more than half of all the resi-
dues in all of UniProt [21, 38].
The ‘‘modeling leverage’’ of a particular 3D structure
(modeling template) depends on several factors, including
(i) the sequence similarity between the template with
known experimental structure and target proteins of
unknown structure, (ii) the method of comparative mod-
eling, and (iii) the criteria by which a model is judged to be
‘‘useful’’. The third factor (what is good enough?) can be
especially difficult to ascertain, and rather inaccurate
models (e.g. just the overall fold) are sufficient for some
important applications of models, while other applications
may require very high accuracy models. Benchmark stud-
ies suggest that sequence similarity of [40% over [50
residues generally provide models with heavy atom root-
mean-square deviations of \2.5 A˚ from the true experi-
mental structure [6, 11, 16, 24–27]. However, templates
that are less sequence similar to the target structure may
provide even higher accuracy models, and models gener-
ated for more sequence similar templates may result in less
accurate models. Leverage also must be defined with
respect to what portion of the target protein can be mod-
eled from the experimental template, leading to metrics for
full protein models, protein domain models, or residue
models per experimental template. Modeling leverage also
needs to be defined with respect to a particular sequence
database; e.g. with respect to a particular version of
UniProt.
Structural coverage
The concept of modeling leverage is intimately associated
with the concept of structural coverage; i.e. the number or
percentage of a particular set of protein sequences,
domains, or residues, which can be modeled from a par-
ticular set of experimental protein templates. Structural
coverage of the protein universe (i.e. a particular version
of UniProt), of an entire proteome of an organism
(e.g. the human proteome), of an ecology of organisms
(e.g. all human gut microorganisms); or of a system of
co-functioning proteins (e.g. proteins associated with a
particular biological process), are all key metrics in mea-
suring the success of SG that depend on the definition of
modeling leverage.
Novel modeling leverage and novel coverage
Related to the concept of modeling leverage is the concept
of novel modeling leverage [22], operationally defined as
the number of proteins/domains/residues that could not be
modeled (based on the above specific definition of lever-
age) as of the date the subject experimental structure was
deposited into the public PDB [22]. The novel leverage
provided by a set of experimental 3D structures across a
particular set of protein sequences defines the novel cov-
erage provided by these structures. This concept of
leveraging experimental structures, and particularly novel
leverage, has been fundamental to the process of target
selection by large-scale centers during PSI-2. In particular,
the large-scale centers systematically target the largest
protein domain families for which we currently have little
or no structural coverage.
The need for a standard convention
The modeling leverage value of a particular experimental
structure, or the coverage of a set of sequences by a set of
structures, depend upon the details of thresholds defined for
sequence similarity that can be expected to provide a
‘‘useful’’ model, as outlined above. There are also certain
technical issues which may or may not be accounted for in
any method of assessing novel leverage. Examples of such
issues, not used in the current work include: (i) while a
sequence may be modeled from a structure already in the
PDB on the date of deposition of subject structure, the
subject structure may allow more accurate modeling of this
sequence, and (ii) one may or may not discount the novel
modeling leverage of a particular structure by the modeling
leverage of experimentally-determined structures subse-
quently deposited in the PDB. It is simply not possible to
define universal thresholds or criteria of model accuracy
that are appropriate for the full range of applications for
which models are used. Thus, the novel leverage reported
for the same data by different groups may vary widely.
Here, we adopt as a convention the definitions and
thresholds proposed by Liu et al. [22] for assessing mod-
eling leverage, novel modeling leverage, and the
corresponding metrics of novel coverage. This is a con-
venient measure of ‘‘modelability’’ that is easily
reproducible with relatively modest computing resources
(the analysis presented here consumed less than 2 CPU-
years).
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Methods
Data set
All data about the status of structural genomics targets
were taken from TargetDB [9]. Leverage, novel leverage,
and the corresponding metrics for coverage were deter-
mined by the method of Liu et al. [22]. The basic concept is
the following. We begin with a fixed version of UniProt, in
this case release 12.8 from Feb 2008; containing 5,678,599
protein sequences with 1,851,231,082 residues. For this
version we compile the number of proteins and residues
that align (PSI-BLAST E-value 10-10, 3 iterations on
UniProt, one on PDB with background estimates based on
UniProt size; for more details see Liu et al. [22]) to any
protein of experimentally determined 3D structure depos-
ited into the PDB at a given time point T = T0. Novel
leverage is then everything that is not covered by this
simple alignment protocol and has arisen from structures
added to the PDB at T1 [ T0; total leverage is computed as
all structures in the PDB covered by this criteria.
Novel structures
We loosely referred to an experimental structure (more
precisely the structure specified by a particular PDB
identifier) as a novel structure if at least 50 residues of this
structure could be used to create novel leverage. This
implies in particular, that novelty was not at all constrained
by any particular definition in terms of the similarity of this
new coordinate set in terms of structure to any other
structure already in the PDB. When compiling per-residue
estimates for novel leverage, we did not apply any such
threshold, instead, any single residue that could not have
been modeled before counted.
Novel leverage versus novel coverage
Leverage and coverage are related metrics that differ
essentially only in the perspective they provide:
Leverage ¼ Number of proteins=residues in database DB
that can be modeled at threshold E ¼ E0
based on a structure added at time T ¼ T0:
ð1AÞ
Coverage ¼ Percentage of proteins=residues in dataset DS
that can be modeled at threshold E ¼ E0
based on a structure added at time T ¼ T0:
ð1BÞ
In the context of this work, we used the DB = UniProt
12.8 (Feb. 2008), E0 = PSI-BLAST E-value \ 10
-10.
Coverage often is compiled with respect to the same
database as leverage, i.e. DS = DB. In fact, this is the
metric that we compiled for this work. However, we have
also compiled coverage values for the set of proteins in
particular organisms, e.g. focusing on the structural
coverage for the human proteome [29]. In principle,
leverage and coverage are symmetric: both can be
compiled on the same data set, and the only essential
difference is that one counts numbers, the other percentages.
Both leverage and coverage can be computed on a per-
structure, on a per-residue or on per-annum base. Fre-
quently, we also compiled those numbers as sums over all
PSI structures in light of the sum over all PDB structures
and/or over all PDB structures without those PSI-structures.
The measures for leverage and coverage as defined
above have a severe problem: they do not distinguish at all
between structures that provide new information and those
that simply confirm the information we already have in the
PDB. This effectively implies that the measures as defined
above do not capture a scientifically relevant reality. This
problem is easy to fix: all we need to do is to compile the
leverage/coverage at a given time and to then define the
novelty provided by new structures as the added leverage
and coverage. We have introduced this simple metric as
‘‘novel leverage’’ and ‘‘novel coverage’’, and defined them
by:
Novel leverage ¼ Number of proteins=residues in
database DB that could first be
modeled at threshold E ¼ E0 based
on a structure added at time T ¼ T0:
ð2AÞ
Novel coverage ¼ Percentage of proteins=residues in
database DB that could first be
modeled at threshold E ¼ E0 based
on a structure added at time T ¼ T0:
ð2BÞ
With the same choices as above: DB = UniProt 12.8,
and E0 = PSI-BLAST E-value \ 10
-10. The deposition
date in the PDB entry decides whether or not a structure is
novel. One important and desired consequence of this
definition is the following. Assume you solved a structure
that has high impact in the sense that many groups use it as
a basis for molecular replacement to do more accurate
structures of the same or of a similar protein sequence.
Then the first structure in this family of structures is rec-
ognized for the novel information it provided on the date it
was deposited in the PDB. The problem that remains and
that we have not addressed convincingly, yet, is how to
measure the benefit of a structure that allows to build better
models for proteins for which we can already build models.
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As indicated by Eq. 2A, only sequences that match to the
sequence of the template with the minimal threshold
(E-value \ 10-10) count.
Results and discussion
Every other novel structure from the USA now from the
PSI
A primary goal of the PSI has been the development of
automation and robotics for large-scale protein structure
determination. It took a few years to scale the pipelines up
to reaching ‘‘high-throughput’’ levels; currently some 600–
800 protein structures per year (i.e. two structures per day).
Progress is evident: over 1,300 structures originated from
the pilot phase PSI-1 (2000–2005), and after 3 of the
5 years of PSI-2, the large-scale centers have already
deposited almost 2,000 new 3D structures. This success is
also evident in the increased contribution from PSI to all
experimental structures deposited into the PDB: over the
course of PSI-2 (2005/07/01–2008/09/19), PSI centers have
contributed almost 9% of all structures world-wide and all
structural genomics (SG) centers have contributed almost
18% of all structures (data not shown). As the PSI is
entirely financed by the NIGMS at the NIH in the USA, its
contribution should be compared directly to structures
deposited into the PDB from US-based laboratories: in the
first 3.25 years of PSI-2 (labeled 2005–2009, where 2009
represents only the first quarter of Year 4), PSI-2 centers
alone had contributed about 18% of all structures deposited
by US structural biology groups (Fig. 1a, cumulative sum
over gray bars). When comparing the annual contribution
from the PSI of novel structures (i.e., \ 30% sequence
identity with any other structure in the PDB at the time of
deposition) to that from all other sources (Fig. 1c), it is
noticeable that the PSI fraction has continued to increase
over its entire duration. Over the last several years, the US
contribution to all structures increases, although the non-
PSI fraction from the US shrinks. Without PSI, the US
structures and even more significantly the US novel
structures would be on decline: the US non-PSI reduction
from 2001 to 2009 is more significant than the reduction of
all other non-PSI contributors over the same time period
(Fig. 1c).
Given that novel leverage is an important criterion in
PSI-2 target selection, PSI-generated structures also pos-
sess more novel leverage than structures from non
Structural Genomic groups (Figs. 1b, d, 3a). The concept
of structural leverage has also been employed in target
selection by non-US Structural Genomics efforts such as
the RIKEN project. Despite competition to structurally
characterize unique sequences, the PSI deposits now
almost as many novel structures as all the other depositors
in the US combined (Fig. 1a), and about 30% of all novel
leverage contributed worldwide (Fig. 1d); the fraction of
novel structures per structure solved is 2–5 times higher for
PSI than for all other depositors (data not shown). In fact,
since 2005, half of the novel leverage generating structures
from the USA was determined by the PSI-2 centers
(Fig. 1a, cumulative sum over blue bars). The contribution
of PSI to the generation of novel leverage is equally
impressive (Fig. 1b, discussed in more detail below).
Worldwide SG contributed about 18% of the structures
since 2005 and about 37% of all novel protein leverage
(171/459 K, Table 1); more than three-quarters of the
novel leverage since 2005 came from PSI-2 centers
(30% = 135/459 K, Table 1).
Structural coverage of sequence space continues to
increase
We froze a version of the entire sequence space known in
Feb. 2008 (UniProt 12.8) and then estimated to what extent
the structures deposited into the PDB at a given time point
could have been used to structurally cover this sequence
universe. We compiled two separate values, one estimating
the per-protein coverage that considers a new arrival to
cover a new protein when at least 50 consecutive residues
were aligned above the threshold (E-value \ 10-10,
Methods; orange in Figs. 1b, 2a), the second a per-residue
coverage, simply an estimate of which fraction of all res-
idues can be structurally covered (purple in Figs. 1b, 2a).
While the former per-protein measure is intuitive, it
requires the definition of an ad hoc threshold (50 residues).
This has to be done because most structures in the PDB
contain single domains while over 75% of proteins in
nature appear to contain multiple domains [19–21, 34]. If
one domain of a protein can be modeled then this consti-
tutes an important advance and ought to be considered.
The PSI contribution to the coverage added by US
structures is now exceeding the 50% mark, i.e. PSI-2
contributes more novel leverage, and hence more coverage
than all other US efforts (Fig. 1b). With this increase, the
US contribution to the novel leverage worldwide continues
to increase (Fig. 1b). Interestingly, the contribution of non-
PSI SG, which peaked in 2004–2007, has contributed rel-
atively little to the worldwide annual novel leverage, while
novel leverage contributions from non-US, non-SG groups
has been relatively constant at *40% annually.
Overall, the structural coverage of UniProt 12.8 increased
slowly, up until about 1992 (Fig. 2a). After that, structural
coverage increased at roughly a constant annual rate. The
growth slowed down slightly toward the onset of structural
genomics, because, despite the continued annual increase
in the number of structures determined, it is getting
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increasingly difficult to succeed for proteins that have so far
eluded structure determination. Novel leverage becomes an
increasingly evasive objective. The advent of structural
genomics countered this development and returned the
growth in structural coverage to almost constant annual
rates. During the course of PSI, the overall structural cov-
erage for UniProt 12.8 has approximately doubled (Table 1)
from *22 to *45% per-protein coverage (Fig. 2a).
If we reset the coverage clock to zero at the beginning of
PSI, and compute the gain over the structural coverage in a
given year (Fig. 2b), we note that between 2000 and 2008
the per-protein structural coverage of UniProt 12.8
increased by about 26 percentage points (Fig. 2b: sum over
all contributions; Table 1: 1,485/5,679 K) corresponding,
by 2008, to an overall per-protein coverage around 45%.
Some 22% of the increase in per-residue and per-protein
structural coverage provided by all structures deposited
worldwide came essentially from four PSI large-scale
centers, compared with *34 and *40% increase in the
structural coverage of UniProt 12.8 by all non-PSI US
and all non-SG, non-US groups, respectively, in the same
time frame (Fig. 2b). Note that the precise values here
depend crucially on the parameters chosen. Our restriction
to E-values B 10-10 implies that the inferred structural
models are of relatively high reliability and cover most of
the aligned regions [16, 25]; higher leverage and coverage
can be achieved at the expense of accuracy [3, 17, 27,
33].
Fig. 1 PSI annual throughput as percentage of the worldwide PDB
and the US-PDB. a Annual statistics for the fraction of structures
determined by the PSI (Protein Structure Initiative at NIH’s NIGMS)
distinguishing between the contribution to all structures deposited in a
given year (gray bars), and the contribution toward novel structures
(blue bars). In this context, we considered any structure that yielded
novel leverage for at least 50 consecutive residues as a ‘‘novel
structure’’. The PSI contribution to novel leverage is 2–3 times higher
than its contribution to all structures. 100% marks all structures
determined by US-laboratories. b While panel (a) shows the fractions
of structures, panel (b) shows the fraction of novel leverage added in
each year (i.e. PSI novel leverage/US-PDB novel leverage), in terms
of per-protein (orange) and per-residue (purple) values. Panels (c)
and (d) distinguish between the contribution from the PSI, from the
US without PSI, from structural genomics (SG) without the PSI and
from all other depositors. In particular, we distinguish the contribu-
tion to all structures (c) and that to all novel leverage (d). Note that in
all figures the years refer to PSI grant years, e.g. 2001 refers to the
period of July 2000–June 2001. The last entry (labeled 2009) marks
an incomplete year from July 2008–September 2008 corresponding to
the first quarter of year 4 of PSI-2
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PSI per-protein gain in novel leverage is 3–4 fold
higher than PDB without PSI
The success of PSI-2 in increasing novel leverage in a
competitive environment is being demonstrated most
clearly when we compile the annual increase in novel
structural coverage per deposited structure. The per-
structure leverage of PSI has consistently been 5–8 times
higher than the corresponding number for non-SG struc-
tures (Fig. 3a). At the same time, the novel leverage of
a deposited experimental structure has decreased
significantly over the past 8 years, both for the PSI, SG
non-PSI, and non-SG structures: it is getting increasingly
difficult to achieve the high novel leverage values that PSI
structures obtained in the earlier years of the program.
Although novel leverage per structure has been drop-
ping, the total number of novel structures solved by PSI
groups has increased in each year of the program. Has this
sufficed to counterbalance the increase in the difficulty of
the task? One answer is provided by Fig. 2b: while the rate
of coverage for non-SG and non-US non-SG groups are
plateauing, the PSI curve has continued to remain almost
Fig. 2 Increase of structural coverage of UniProt. Plotted are the
percentage of proteins (orange with crossed squares) and residues
(purple with open squares) in the entire UniProt database (release
12.8 Feb. 2008) that potentially be modeled using one of the
structures in the PDB as a template, where ‘‘modelability’’ is based on
PSI-BLAST alignments (E-value \ 10-10) between the sequence of
the target and the sequence of the template of known structure. Panel
(a) shows the percentage of UniProt with structural coverage, per
year, while panel (b) on the right (coloring as in Fig. 1) zooms in to
showing the gain in coverage with respect to the onset of PSI (July
2000). Note that the absolute values of coverage depend crucially on
the values chosen for what is considered to be an acceptable model.
Our choices of E-values \ 10-10 provide relatively conservative
estimates for high-accuracy models
Table 1 Structural coverage of UniProt
Number of
proteins (in Kilo)
Number of
residues (in Mega)
PSI novel leverage
proteins (Kilo)
SG novel leverage
proteins (Kilo)
PSI novel leverage
residues (Mega)
SG novel leverage
residues (Mega)
UniProt
12.8
5,679 1,851 – – – –
3D
coverage
2000
1,389 403 – – – –
New 3D
2000–
2008
1,485 349 319 457 64 90
New 3D
2005–
2008
459 104 135 171 27 33
All values are compiled with respect to UniProt version 12.8; 3D coverage 2000, marks the structural coverage compiled as specified in Methods
(10-3 PSI-BLAST) that could have been achieved on UniProt 12.8 with the structures in the PDB by June 30, 2000; New 3D 2000–2008, marks
the addition of structural coverage over the course of the PSI (from July 1, 2000 to September 16, 2008); New 3D 2005–2008, marks the addition
of structural coverage over the course of PSI-2 (from July 1, 2005 to September 16, 2008)
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linear. Another answer is provided by the contribution to
the coverage per deposited structure with respect to the
average annual contribution by the following ratio of
fractions:
Q ¼
novel coverage generated by effort X in year Y
number of protein structures deposited by X in Y
 
novel leverage generated by PDB in Y
number of proteins deposited in Y
  ð3Þ
shown annually for various efforts in Fig. 3b. Values below
1 imply that effort X contributed less to the coverage per
structure than the average over the entire PDB. PSI has
consistently contributed over 3 times more than average
(Fig. 3b). The contribution of non-PSI SG has also been
very high, but in recent years non-PSI SG has reduced to
levels just above 1.
PSI has by now targeted and worked on most of the
largest 16,787 sequence-structure families with prokaryotic
representatives. PSI-2 continues to pick the largest
remaining families, however, those become smaller. The
novel leverage of all non-PSI structures in the PDB is also
decreasing. This is partly due to the same reason: the
largest families are either structurally covered or continue
to evade structure determination. Furthermore, as already
discussed, the generation of novel leverage becomes
increasingly challenging.
Does this imply that attempts at experimentally deter-
mining structures for new sequence-structure families will
be doomed? Despite efforts in optimizing novel leverage
and providing structures for as yet uncharacterized domain
sequence families, structural genomics has not discovered
many truly novel structures [1, 5, 7, 8, 13, 15, 18]. Indeed,
the discovery of previously unobserved protein structure
space (new geometries and principles not seen before) is
becoming increasingly difficult [22]. This implies that (i)
we now know most protein structure geometries or folds
and (ii) on average, staying within the vicinity of known
structures is more likely to result in a successful structure
determination. By design, PSI-2 has been attempting and
succeeding in targeting proteins which are not similar to
proteins with known structures, i.e. to increase the odds of
discovering new territories through their development of
high-through pipelines and technologies. To rephrase this
in a common analogy: by focusing on protein domain
families with no structural representatives PSI-2 has sys-
tematically targeted and succeeded in reaching ‘‘higher-
hanging fruits’’.
Many other criteria for success
Structural genomics, by design, is a hypothesis-generating
instead of a hypothesis-driven endeavor. It shares this
aspect with many new high-throughput genomics projects
in the evolving molecular biology discipline although—
unlike other genomics projects—structural genomics con-
tinues to generate very high-resolution, detailed molecular
data. The success of the PSI is reflected by many aspects
which range from increasing the speed of structure deter-
mination and deposition (both dramatically increased
Fig. 3 Per-structure estimates of novel leverage. The left panel (a)
demonstrates how the non-cumulative (annual) novel leverage for
UniProt 12.8 per deposited structure decreases over time because the
task of generating high novel leverage becomes increasingly difficult.
The right panel (b) reports the relative annual coverage per deposited
structure (Q, Eq. 3). Values Q below 1 mark contributions below the
average over the entire PDB in the year. While the relative values
given in Fig. 1 vary little with the particular threshold for what is
considered to be a ‘‘useful model’’, the absolute values given in Fig. 2
and Fig. 3 depend crucially on the values chosen for what is
considered to be an acceptable model. Coloring as in Fig. 1: pink with
open circle: PSI alone; blue with open squares: structures from US
labs excluding structures claimed by PSI; red with filled triangle: SG
structures from non-PSI efforts; green with filled diamonds: structures
from outside the US not claimed by any SG consortium
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during this decade), through high literature impact and
extreme reduction in the number of papers per structure to
the push of automation and robotics which increases the
diverse biophysical measurements readily available to
researchers in related fields with different expertise.
Objective criteria that allow the monitoring of the
degree to which scientific endeavors deliver what they
promised are naturally becoming integral parts of a land-
scape in which the funding for science shrinks, while the
challenges for the scientist arguably increase, and in which
an increasing fraction of all science is funded by temporal
grants. Here, we have demonstrated that PSI-2 has been
extremely successful by the aims it posed at the start: it
contributed substantially toward the increase of novel
leverage to the extent that a future without PSI will clearly
imply a considerable lengthening of the time needed to
cover today’s protein universe.
Given that the PSI was successful in meeting the mile-
stones that the PSI commission posed, the aim now is to
finish with a wider perspective that considers the optimi-
zation of structural coverage as a means and not as an end.
One aspect of structural genomics is the adventure of
mapping unknown spaces. We seek connections to create
maps. These objectives require the coincidence of a wealth
of sequences and structures in spaces that have hardly been
experimentally covered (i.e. families of unknown function)
but appear to be extremely important, as demonstrated by
the annotations for the universal family of EVE/PUA/PUA-
like proteins enriched by structural genomics [5]. All these
connections contribute to the understanding of protein
evolution. The PSI has covered an immense fraction of the
prokaryotic sequence-space in terms of generating proto-
cols, reagents, and experimental data. This wealth is
available today through the PSI Materials Repository
(http://www.hip.harvard.edu/gateway/) and through the PSI
Knowledge Base (http://kb.psi-structuralgenomics.org/). A
relatively small fraction of the target families have so far
yielded experimental structures, but this ‘‘small’’ fraction
now contributes over one-third of the novel leverage
worldwide, providing structural templates for over 300,000
new reliable protein structure models.
Another long-term impact is the contribution toward
making structure become an integral part of molecular
biology and toward converting structure determination
from an amazing art mastered by few into a pipeline
accessible to many. Clearly the cost reduction, the devel-
opment of sophisticated semi-automated high throughput
pipelines contributed immensely to making this happen.
Without structural genomics, today’s level of automation
would not have been reached at all. The development of
cheaper sequencing techniques was certainly no goal of the
human sequencing project. But those techniques have been
changing biology immensely over the last decade.
16–20 years to go to complete coverage of sequence
universe?
How much more is left to do? The following rationale
provides an over simplified answer. Firstly, we have esti-
mated that at least 20% of all residues in proteomes are
not viable targets for structural genomics because they
encode complex integral membrane proteins, long contin-
uous coiled-coils regions, long regions that are natively
unstructured, and leftovers from partial models (e.g. model
A covers domain D1 from residues 6–55, model B covers
domain D2 from residues 61–100 in a protein of 100 res-
idues; this leaves 10 residues 1–5 and 56–60 as non-viable
targets) [21]. Most of these 20% of the residues are in short
regions not assigned to a particular domain and are prob-
ably some sort of domain linkers and embellishments. Put
differently, 80% per-residue coverage implies ‘‘comple-
tion’’. Secondly, today’s coverage is about 40%, i.e. 40%
(80–40) remains to be done. Thirdly, extrapolating from
Fig. 2a, we might estimate the average annual per-residue
growth in coverage of UniProt 12.8 to be about 2.5%.
Assuming this rate to hold for the future, we would esti-
mate 16 years (40/2.5 = 16) to structurally cover whatever
remains of the UniProt 12.8 sequence database. While
sequence space continues to grow, much of this new
growth maps to domain families covered by this 80% of
current proteins sequence universe.
Clearly, the assumption of identical growth is overly
optimistic: the rate has been kept at a linear growth only
due to the focused effort of structural genomics. Given that
PSI-2 has already cloned almost all the largest viable
families, it is clear that the future leverage will be lower.
Moreover, as new genomes are sequenced, only a fraction
of these sequences map to known protein domain families,
and the uncovered protein universe continues to grow.
Furthermore, it might be argued that the 40% of the res-
idues that remain to be structurally explored will constitute
proteins that are much more challenging for structure
determination than those in the 40% of the residues that are
covered today. If so, structural genomics methods might fail
to capture those residues in these much more challenging
classes of proteins, and our assumption of a constant growth
rate might be inappropriate. True, this might be so, and we
have no scientific argument to dispel this concern. However,
we can move back into the past and pretend to estimate for
what was then the future: e.g. if we had taken the growth rate
from 1994 to 2000 to estimate the coverage of 2008, we
would have been completely right (Fig. 2a).
Where from here?
We have established structural genomics as an extremely
efficient way to discover new areas in the protein universe
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that will undoubtedly continue to invoke testable hypoth-
esis for years to come. Will the trend continue? Can we
extrapolate from today’s data, or will we need something
completely different to efficiently cover what remains?
Clearly, we have to improve structural determination for
sequence-structure families from eukaryotes. Today, it
requires some 5–10-fold more resources to determine the
structure for an average eukaryotic protein than for an
average prokaryotic protein. A considerable fraction of the
untouched sequence space falls into sequence-structure
families that exclusively represent eukaryotes. Clearly,
targeting this important domain becomes an important
objective. Another fact of PSI-2 was that structure deter-
mination has so far succeeded for less than 30% of all
families targeted. Developing techniques that allow a
substantial increase in this yield appears to be another
important goal.
The final question seems to be hovering around the issue
of how much will the part of the universe without structural
coverage differ from the part we cover today? Clearly, we
need to find ways to make structural genomics work for
types of proteins for which it has so far had only limited
success, including membrane proteins, eukaryotic proteins,
and secreted proteins. Are there any new structural prin-
ciples out there that remain to be discovered and that
totally elude today’s techniques for structure determina-
tion? Biology is so full of innovation and surprise that the
answer will clearly be in the affirmative. To which extent
this will be the case remains utter speculation. However,
we have strong evidence that a considerable part of what is
left falls into the category of proteins that are unusually
flexible, or intrinsically unstructured and that possibly do
not adopt regular structures without a binding partner. Do
we therefore have to step up in terms of complexity and
attack the problem of a structural genomics for complexes?
Clearly, this will be one of the important challenges for
both the short-term and long-term of structural genomics.
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